Stage and Site Specific Sensitivity of Fecal Immunochemical Tests for Large Advanced Adenomas and Cancers
Project/Area Number |
25460785
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Epidemiology and preventive medicine
|
Research Institution | National Cancer Center Japan |
Principal Investigator |
Matsuda Takahisa 国立研究開発法人国立がん研究センター, 中央病院, 検診センター長 (30508049)
|
Co-Investigator(Kenkyū-buntansha) |
KAKUGAWA Yasuo 国立がん研究センター中央病院, 内視鏡科, 医長 (00537889)
OONO Yasuhiro 国立がん研究センター東病院, 消化管内視鏡科, 医員 (50602025)
|
Project Period (FY) |
2013-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
|
Keywords | 大腸癌 / スクリーニング / 便潜血検査 / 診断感度 / 部位別検討 / 便潜血検査免疫法 / 大腸腫瘍 / 便潜血 / 免疫法 / 定量化 |
Outline of Final Research Achievements |
Although fecal immunochemical test (FIT) has been widely adopted in many population based colorectal cancer (CRC) screening programs, its stage- and anatomical site-specific sensitivity for advanced colorectal neoplasms remains unclear. A total of 333 subjects [mean age: 63.9years, 176 males (52.9%)]with advanced neoplasms were prospectively enrolled. Of them, 219 had cancerous lesions [Tis (carcinoma in situ):54, T1:48, and T2 to T4:117]. The sensitivity of FIT for advanced adenoma, Tis, T1, and T2-4 cancers were 45.6% (36.3-55.2%), 48.1% (34.5-62.0%), 77.1% (62.3-87.5%), and 91.5% (84.5-95.6%), respectively. FIT had significantly lower sensitivity for proximally located lesions than distal ones in advanced adenomas (34.8% vs. 60.4%, P=0.008), cancers (64.5% vs. 84.6%, P=0.001), and invasive cancers (76.0% vs. 92.2%, P=0.006). FIT had significantly lower sensitivity for proximal located and early cancerous lesions.
|
Report
(4 results)
Research Products
(3 results)